/C O R R E C T I O N -- Today's Marketplace/
Annovis Bio (NYSE: ANVS) recently showcased its breakthrough drug development for neurodegenerative diseases on Today's Marketplace. CEO Maria Maccecchini and Dr. Scott Shipman discussed the company's promising clinical trials targeting Alzheimer's and Parkinson's diseases.
The company's once-daily pill uniquely targets multiple toxic proteins, including plaques, tangles, and Lewy bodies that kill nerve cells in the brain. Clinical studies have demonstrated not just slowed progression but actual improvement in symptoms - enhanced cognition in early Alzheimer's patients and improved cognition and function in Parkinson's patients.
With over 7 million people affected by neurodegeneration in the United States, the impact extends beyond patients to caregivers and healthcare workers. The company is currently seeking funding for next-phase trials of this potentially groundbreaking treatment.
Annovis Bio (NYSE: ANVS) ha recentemente presentato lo sviluppo della sua innovativa terapia per le malattie neurodegenerative nel Marketplace di Oggi. L'amministratore delegato Maria Maccecchini e il Dott. Scott Shipman hanno discusso dei promettenti studi clinici dell'azienda mirati alle malattie di Alzheimer e Parkinson.
La pillola, assunta una volta al giorno, è in grado di colpire in modo unico moltissimi proteine tossiche, tra cui placche, grovigli e corpi di Lewy, che uccidono le cellule nervose nel cervello. Gli studi clinici hanno dimostrato non solo un rallentamento della progressione, ma anche un reale miglioramento dei sintomi - una maggiore cognizione nei pazienti con Alzheimer precoce e un miglioramento della cognizione e della funzionalità nei pazienti con Parkinson.
Con oltre 7 milioni di persone colpite da neurodegenerazione negli Stati Uniti, l'impatto si estende oltre i pazienti, coinvolgendo anche i caregiver e i lavoratori sanitarî. L'azienda è attualmente alla ricerca di finanziamenti per le prove cliniche della fase successiva di questo trattamento potenzialmente rivoluzionario.
Annovis Bio (NYSE: ANVS) recientemente presentó el desarrollo de su innovador fármaco para enfermedades neurodegenerativas en el Marketplace de Hoy. La CEO Maria Maccecchini y el Dr. Scott Shipman discutieron sobre los prometedores ensayos clínicos de la compañía dirigidos a las enfermedades de Alzheimer y Parkinson.
La pastilla de una vez al día ataca de manera única múltiples proteínas tóxicas, incluyendo placas, enredos, y cuerpos de Lewy que matan las células nerviosas en el cerebro. Los estudios clínicos han demostrado no solo un retraso en la progresión, sino también una mejora real en los síntomas: mejor cognición en pacientes con Alzheimer temprano y una mejora en la cognición y función en pacientes con Parkinson.
Con más de 7 millones de personas afectadas por la neurodegeneración en los Estados Unidos, el impacto se extiende más allá de los pacientes a los cuidadores y trabajadores de la salud. La compañía está actualmente buscando financiamiento para los ensayos de la próxima fase de este tratamiento potencialmente innovador.
안노비스 바이오 (NYSE: ANVS)는 최근 오늘의 마켓플레이스에서 신경퇴행성 질환에 대한 혁신적인 약물 개발을 선보였습니다. CEO인 마리아 마체치니와 박사 스콧 쉽맨은 알츠하이머 및 파킨슨병을 겨냥한 회사의 유망한 임상 시험에 대해 논의했습니다.
하루에 한 번 복용하는 이 알약은 신경세포를 죽이는 플라크, 엉킴, 루이체 등 여러 독성 단백질을 독특하게 표적으로 삼고 있습니다. 임상 연구들은 질병의 진행을 늦출 뿐만 아니라 실제로 증상의 개선을 보여주었습니다 - 초기 알츠하이머 환자에서 향상된 인지 능력과 파킨슨 환자에서의 인지 및 기능 향상입니다.
미국에서 700만 명 이상의 신경퇴행성 질환 환자가 있으며, 그 영향은 환자를 넘어 간병인과 의료 종사자에게까지 미칩니다. 회사는 현재 이 혁신적 치료의 다음 단계 임상을 위한 자금을 찾고 있습니다.
Annovis Bio (NYSE: ANVS) a récemment présenté le développement de son médicament révolutionnaire pour les maladies neurodégénératives sur le Marketplace d’aujourd’hui. La PDG Maria Maccecchini et le Dr. Scott Shipman ont discuté des essais cliniques prometteurs de l'entreprise ciblant les maladies d'Alzheimer et de Parkinson.
La pilule prise une fois par jour cible de manière unique plusieurs protéines toxiques, y compris les plaques, les enchevêtrements et les corps de Lewy, qui tuent les cellules nerveuses dans le cerveau. Les études cliniques ont démontré non seulement un ralentissement de la progression, mais aussi une réelle amélioration des symptômes - une cognition améliorée chez les patients souffrant d'Alzheimer à un stade précoce et une amélioration de la cognition et de la fonction chez les patients atteints de Parkinson.
Avec plus de 7 millions de personnes affectées par la neurodégénérescence aux États-Unis, l'impact va au-delà des patients pour inclure les soignants et les travailleurs de la santé. L'entreprise recherche actuellement un financement pour la prochaine phase des essais de ce traitement potentiellement révolutionnaire.
Annovis Bio (NYSE: ANVS) hat kürzlich seine bahnbrechende Medikamentenentwicklung für neurodegenerative Erkrankungen im heutigen Marktplatz vorgestellt. CEO Maria Maccecchini und Dr. Scott Shipman diskutierten über die vielversprechenden klinischen Studien des Unternehmens, die auf Alzheimer und Parkinson abzielen.
Die einmal täglich einzunehmende Pille zielt einzigartig auf mehrere toxische Proteine ab, darunter Plaques, Verwicklungen und Lewy-Körper, die Nervenzellen im Gehirn abtöten. Klinische Studien haben nicht nur ein verlangsamtes Fortschreiten gezeigt, sondern auch eine tatsächliche Verbesserung der Symptome - eine verbesserte Kognition bei frühen Alzheimer-Patienten und verbesserte Kognition und Funktion bei Parkinson-Patienten.
Mit über 7 Millionen Menschen, die in den Vereinigten Staaten von Neurodegeneration betroffen sind, reicht die Auswirkung über die Patienten hinaus und betrifft auch Pflegekräfte und Gesundheitsarbeiter. Das Unternehmen sucht derzeit nach Finanzierung für die nächsten Phase der klinischen Studien zu dieser potenziell bahnbrechenden Behandlung.
- None.
- None.
In the news release, Annovis CEO Discusses Breakthrough Drug for Neurodegenerative Diseases on Today's Marketplace, issued 04-Dec-2024 by Today's Marketplace over PR Newswire, we are advised by the company that in the Annovis boilerplate, the first sentence should include the stock ticker (NYSE: ANVS) as originally issued inadvertently. The complete, corrected release follows:
Annovis CEO Discusses Breakthrough Drug for Neurodegenerative Diseases on Today's Marketplace
"We have over 7 million people with neurodegeneration in
Dr. Maccecchini went on to explain that Annovis is seeking funding for the next phase trials of a drug in development that attacks the root causes of Alzheimer's and Parkinson's diseases and could help millions of patients.
Annovis' once-a-day pill is safe and works in both diseases, and their studies have shown that it does not just slow the progression but actually improves the symptoms. In early Alzheimer's patients it improves cognition, and in Parkinson's patients it improves cognition and function.
"Most people have heard of plaque in Alzheimer's and maybe Lewy bodies in Parkinson's," Dr. Maccecchini explained. "Our drug attacks plaque, tangles, and Lewy bodies. It targets the toxic proteins that kill nerve cells in the brain, and it addresses more than one. If you have more than one toxic protein, just removing one still leaves others to kill nerve cells. Our drug actually protects nerve cells from dying."
Dr. Shipman said that he is excited about the breakthroughs companies like Annovis are developing to stop the impact that neurodegenerative diseases inflict on patients and their families. However, he also wanted to remind the audience of the global implications of such diseases and the impact that innovative solutions can have on healthcare overall.
"We need to think about not just the patient but the families and caregivers that also serve that patient and the healthcare workforce that is required to care for patients with neurodegenerative and other diseases," he told King. "If we can keep patients healthier longer, we can reduce the burden on the healthcare workforce and allow that limited resource to stretch further."
TMP produces compelling interviews covering complex and important topics for syndication across the financial news media landscape, targeting investors, journalists, financial professionals, and interested viewers. "It was an incredible experience to speak on TMP and share insights about our work at Annovis. I encourage viewers to tune in and explore more about the meaningful progress we're making," added Dr. Maccecchini.
About Annovis
Headquartered in
About
The Institute for Population Health is a hub for integrating population health research, teaching, and service across the University, health systems, and communities through effective, authentic partnerships that advance health equity and improve access to high-value care. For more information visit https://www.creighton.edu/institute-population-health
About Today's Marketplace
Today's Marketplace (TMP) is a series of C-Suite interviews filmed at the prestigious New York Stock Exchange (NYSE) and the NASDAQ MarketSite studio for earned media and targeted institutional and retail investor distribution. Learn more about TMP by visiting: todaysmarketplace.tv.
For More Information Contact:
Today's Market Place
Dian Rygh, producers@cmghd.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/annovis-ceo-discusses-breakthrough-drug-for-neurodegenerative-diseases-on-todays-marketplace-302321849.html
SOURCE Today's Marketplace
FAQ
What is the main breakthrough in Annovis Bio's (ANVS) new drug for neurodegenerative diseases?
How does Annovis Bio's (ANVS) drug treat both Alzheimer's and Parkinson's diseases?
What are the current development stages for Annovis Bio's (ANVS) neurodegenerative drug as of December 2024?
How many people could potentially benefit from Annovis Bio's (ANVS) new drug in the United States?
